Intra-tumour heterogeneity : going beyond genetics
© 2016 Federation of European Biochemical Societies Cancer patients die primarily due to disease recurrence after transient treatment responses. The emergence of therapy-resistant escape variants is fuelled by intra-tumour heterogeneity, underpinned by interference and Darwinian evolution among cont...
Saved in:
Published in | The FEBS journal Vol. 283; no. 12; pp. 2245 - 2258 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley & Sons, Inc
01.06.2016
Blackwell Publishing Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | © 2016 Federation of European Biochemical Societies
Cancer patients die primarily due to disease recurrence after transient treatment responses. The emergence of therapy-resistant escape variants is fuelled by intra-tumour heterogeneity, underpinned by interference and Darwinian evolution among continuously developing sub-clones in the mutating tumour. Novel cancer cell variants build upon the pre-existing genetic landscape and tumour heterogeneity is often ascribed largely to genetic variability. While mutations are required for cancer development and studies of genetic evolution of tumours have improved our understanding of cancer biology, genetics only represents one dimension of the fitness of each cancer cell. Beyond the mutations, several non-genetic factors also add significant variability, resulting in a complex and highly dynamic tumour cell population that can drive disease under almost any condition. This viewpoint article summarizes the genetic basis of intra-tumour heterogeneity, before dissecting four major interdependent non-genetic factors we think critically contribute to the overall variability of tumour cells in all types of cancer: epigenetic regulation, cellular differentiation hierarchies, gene expression stochasticity and tumour microenvironment. We finally present the relevant technological approaches to address the combined contribution of both genetic and non-genetic factors to intra-tumour heterogeneity, focusing on genomic profiling, cellular lineage tracing and single-cell RNA sequencing technologies. This strategy will ultimately allow dissection of the full range and depth of intra-tumour heterogeneity. We thus believe that understanding how cancer genetics synergize with the emerging non-genetic factors will be key for development of therapies able to tackle tumour escape and thereby improve cancer patient survival.
Our work was funded by Associação Portuguesa Contra a Leucemia (APCL-SEMAPA 2014 to HN) and Fundação para a Ciência e Tecnologia (FCT) through individual fellowships (SFRH/BPD/91344/2012 to FC; SFRH/BCC/105888/2014 and SFRH/BPD/112968/2015 to HN) and a FCT research grant (EXPL/BIM-ONC/1656/2013 to HN). |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 1742-464X 1742-4658 |
DOI: | 10.1111/febs.13705 |